Back to Search Start Over

PALLiative care in ONcology (PALLiON): A cluster-randomised trial investigating the effect of palliative care on the use of anticancer treatment at the end of life.

Authors :
Hjermstad MJ
Pirnat A
Aass N
Andersen S
Astrup GL
Dajani O
Garresori H
Guldhav KV
Hamre H
Haukland EC
Jordal F
Lundeby T
Løhre ET
Mjåland S
Paulsen Ø
Semb KA
Staff ES
Wester T
Kaasa S
Source :
Palliative medicine [Palliat Med] 2024 Feb; Vol. 38 (2), pp. 229-239. Date of Electronic Publication: 2024 Jan 09.
Publication Year :
2024

Abstract

Background: Effects on anticancer therapy following the integration of palliative care and oncology are rarely investigated. Thus, its potential effect is unknown.<br />Aim: To investigate the effects of the complex intervention PALLiON versus usual care on end-of-life anticancer therapy.<br />Design: Cluster-randomised controlled trial (RCT), registered at ClinicalTrials.gov (No. NCT03088202). The complex intervention consisted of a physician education program enhancing theoretical, clinical and communication skills, a patient-centred care pathway and patient symptom reporting prior to all consultations. Primary outcome was overall use, start and cessation of anticancer therapy in the last 3 months before death. Secondary outcomes were patient-reported outcomes. Mixed effects logistic regression models and Cox proportional hazard were used.<br />Setting: A total of 12 Norwegian hospitals (03/2017-02/2021).<br />Participants: Patients ⩾18 years, advanced stage solid tumour, starting last line of anticancer therapy, estimated life expectancy ⩽12 months.<br />Results: A total of 616 (93%) patients were included (intervention: 309/control:307); 63% males, median age 69, 77% had gastrointestinal cancers. Median survival time from inclusion was 8 (IQR 3-14) and 7 months (IQR 3-12), and days between anticancer therapy start and death were 204 (90-378) and 168 (69-351) (intervention/control). Overall, 78 patients (13%) received anticancer therapy in the last month (intervention: 33 [11%]/control: 45 [15%]). No differences were found in patient-reported outcomes.<br />Conclusion: We found no significant differences in the probability of receiving end-of-life anticancer therapy. The intervention did not have the desired effect. It was probably too general and too focussed on communication skills to exert a substantial influence on conventional clinical practice.<br />Competing Interests: Declaration of conflicting interestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Details

Language :
English
ISSN :
1477-030X
Volume :
38
Issue :
2
Database :
MEDLINE
Journal :
Palliative medicine
Publication Type :
Academic Journal
Accession number :
38193250
Full Text :
https://doi.org/10.1177/02692163231222391